X4 Pharmaceuticals (XFOR) Operating Income Growth (3y) (2020 - 2026)
Powered by 
Analysis
X4 Pharmaceuticals (XFOR) Operating Income Growth (3y) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | 7.09% |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | 12.54% |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | 51.64% |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | 19.17% |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | 7.73% |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | -15.60% |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | BeOne Medicines | 40.49 Bn | 35.39 Bn | 1.53 Bn | 44.54% |
| 9 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | 53.28% |
| 10 | X4 Pharmaceuticals | 510.43 Mn | 315.33 Mn | 7.19 Mn | 14.04% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 14.04% |
| Mar 31, 2026 | 11.51% |
| Dec 31, 2025 | 2.51% |
| Sep 30, 2025 | -10.93% |
| Jun 30, 2025 | -8.44% |
| Mar 31, 2025 | 23.71% |
| Dec 31, 2024 | -7.12% |
| Sep 30, 2024 | -21.75% |
| Jun 30, 2024 | 79.08% |
| Mar 31, 2024 | -27.63% |
| Dec 31, 2023 | -12.59% |
| Sep 30, 2023 | -17.03% |
| Jun 30, 2023 | -20.75% |
| Mar 31, 2023 | -40.43% |
| Dec 31, 2022 | -32.99% |
| Sep 30, 2022 | -5.89% |
| Jun 30, 2022 | -15.32% |
| Mar 31, 2022 | -26.78% |
| Dec 31, 2021 | -53.37% |
| Sep 30, 2021 | -30.79% |